ACTIVE MATERS

Ms. Boukle Ellen (email: boukje.ehlen@maastrichtuniversity.nl ) has joined as the project manager for Immunosarbor. She brings extensive experience with European grants, which will be invaluable to the project's success.

A new student assistant, Feline Geels, has joined our team. Her role involves assisting with remote data monitoring, which is crucial for ensuring data cleaning and completeness before data analysis

On-site monitoring for the ImmunoSABR project has officially started. Following the completion of remote monitoring at all 11 centers, on-site monitoring visits have been scheduled for 8/11 of the centers between November 24 and December [...]

We are currently in discussions with the company Ingedata to segment lesions in imaging data from patients in the Immunosarbor trial. This will give us information on how drug ImmunoSABR affects lesions in time. In [...]

We have established a contract with company “BaseClear” for microbiome analysis of the collected samples (both control arm and experimental arm). Our goal is to externally validate and publish microbiome signatures that serve as prognostic [...]

We recently signed an agreement with the company “Qualiblood” to analyze blood samples from patients enrolled in immunosabr. This analysis will test new circulating hypoxia biomarkers, not only in patients but also in mice with [...]

We are collaboration with a bioinformatician from Maastricht University Medical Centre (MUMC+), who will conduct data analysis for ImmunoSABR focused on identifying both responders and non-responders of patients enrolled in the study.

We have established an agreement with KU Leuven to analyze immunological serum biomarkers in blood samples from patients enrolled in ImmunoSABR. The analysis will utilize a targeted approach with the sFIS assay, enabling detailed insights [...]